Drug intelligence / Profile preview

cadralazine

Development stage: Discontinued
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

Cadralazine is an antihypertensive drug belonging to the class of hydrazinophthalazines. It is a direct-acting vasodilator that works by relaxing vascular smooth muscle, primarily in arterioles, leading to decreased peripheral resistance and lower blood pressure. The mechanism of action involves interference with calcium transport in vascular smooth muscle cells, resulting in relaxation and vasodilation. Cadralazine was developed as part of efforts to create effective oral antihypertensive agents.

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on cadralazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cadralazine.

Explore the full profile